ACE2 and carcinoma: A similar analysis for the 13 approved antidiabetic drugs in the CMAP dataset that were tested on the same four carcinoma cell lines did not identify any individual or class of drugs that significantly altered ACE2 expression, partly due to the small number of drugs in this class (Table EV1D and E).